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Abstract: Glaucoma is undergoing a paradigm shift and transitioning from merely disease staging to evidence-based risk assessment of 
in the individual patient.  
Initially introduced for ocular hypertensive patients, risk assessment calculators  are now being developed for patients with established 
glaucoma. 
  All persons at risk will not develop glaucoma, and some 
persons do so even without identifiable risk. These tenets are 
at the core of the conceptualization of risk assessment for 
glaucoma. By refining the predictive value of end of the 
various risk factors, this concept can evolve [1, 2]. 
LESSONS FROM CARDIOVASCULAR MEDICINE 
  Population-based, prospective, epidemiologic research 
provides valuable insights into the prevalence, incidence, 
predisposing conditions, prognosis and clinical continuum of 
disease. Based on pathologic observations and metabolic 
investigation, dyslipidemia was recognized as a fundamental 
risk for accelerated atherogenesis. Moreover, other 
measurable and correctable predisposing conditions, such as 
hypertension and diabetes, also were demonstrated to be risk 
factors. Clinical trials showed modification of some of these 
predisposing risk factors substantially reduced the risk of 
coronary heart disease (CHD). Aggregation of this evidence 
has provided the foundation for the development of 
guidelines on the prevention, recognition, and management 
of risk factors for CHD. It also stimulated the development 
of risk calculators [2-5].
 
  Based on a considerable body of work, Framingham 
Study-based multivariable risk assessment calculators now 
are widely used to estimate the 10-year probability of a 
coronary event for dyslipidemia. Such calculators depend on 
the level of blood lipids and the burden of coexisting risk 
factors, including age, systolic blood pressure, hypertension 
treatment, and cigarette smoking. These risk calculators 
promote cost-effective targeting of CHD candidates for 
controlling blood lipids. They also provide for more 
cost-effective therapy, as treatment is directed to the patients 
for whom it is most appropriate. 
STRATEGIES FOR GLAUCOMA RISK ASSESSMENT 
  Glaucoma is undergoing a paradigm shift and 
transitioning from merely disease staging to evidence-based  
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risk assessment of the individual patient. Initially introduced 
for ocular hypertensive patients, risk assessment calculators 
[6] are now being developed for patients with established 
glaucoma [7-9]. 
  A broad range of management options exists for patients 
with ocular hypertension. Ultimately, the patient and the 
ophthalmologist collaborate in determining if, or when, 
therapy will be initiated. Safety, efficacy, cost and 
convenience are all factors that impact the decision to treat. 
Evidence-based risk assessment aids in determining whether 
treatment is warranted in a particular patient. Although this 
evidence is limited, consideration of risk factors, disease 
progression risks, and life expectancy help to determine if 
treatment is appropriate. Glaucoma risk assessment should 
evolve toward greater refinement with the availability of new 
evidence, just as CHD risk assessment has evolved. New 
clinical trials, long-term follow-up of ongoing studies, and 
contributions from research into the pathogenesis and 
treatment of glaucoma all are needed to continue to refine 
this model. 
LIMITATIONS OF GLAUCOMA RISK ASSESSMENT 
  Considerable data still are lacking to optimally achieve 
the development of definitive management guidelines for 
ocular hypertension. In contrast to CHD, in which the study 
endpoints clearly reflect an untoward impact on quality of 
life, the endpoints currently used for glaucoma studies are 
limited to progression based on visual field testing or 
observation of the optic nerve. Thus, it is critical to define 
the period between the development of glaucoma and 
progression to significant visual loss and blindness in 
longitudinal trials. Additionally, the effect of additional 
potential risk factors, such as diabetes mellitus, hypertension, 
and family history, requires further study. Also, because of 
the limited sample size, studies such as OHTS/EGPS have 
not been able to evaluate a number of risk factors. The 
limited power of these studies could have resulted in a risk 
factor being declared as non-significant when in fact it is. 
Methodological limitations also resulted in well-known risk 
factors, such as family history, not being incorporated into 
the calculator. Research also is needed to clarify the role of 
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  Point estimates of relative risk for evaluated risk factors 
are relatively imprecise, as indicated by relatively large 
confidence intervals. This indicates a need for studies with 
larger samples. Current calculators refer only to baseline 
values. They do not take into account follow-up history. 
Calculators have not been validated in blacks or Asians. 
Although the OHTS includes blacks, the EGPS did not. Only 
a limited proportion of OHT patients actually fit into the 
description of OHTS/EGPS. 
  With these data, one can refine the multivariate risk 
factor assessment. Then a number-needed-to-treat analysis, 
preferably based on progression to significant visual 
impairment rather than on progression to glaucoma alone, 
and eventually a cost-effective analysis could be produced. 
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